TY - JOUR T1 - Addressing unmet needs in the treatment of COPD JF - European Respiratory Review JO - EUROPEAN RESPIRATORY REVIEW SP - 333 LP - 344 DO - 10.1183/09059180.00004014 VL - 23 IS - 133 AU - Francesco Patalano AU - Donald Banerji AU - Peter D’Andrea AU - Robert Fogel AU - Pablo Altman AU - Paul Colthorpe Y1 - 2014/09/01 UR - http://err.ersjournals.com/content/23/133/333.abstract N2 - The burden of chronic obstructive pulmonary disease (COPD) is considerable, both socially and economically. Central to COPD management is the use of long-acting bronchodilators, which provide patients with optimal bronchodilation and improvements in symptoms. The once-daily, long-acting β2-agonist indacaterol, the long-acting muscarinic antagonist glycopyrronium, and the indacaterol/glycopyrronium fixed-dose combination QVA149 have all been shown to significantly improve lung function and patient-reported outcomes. The ability to take medication appropriately is important. Easy to use, low resistance devices may help patients take their medication and achieve good drug deposition. There is a need to optimise COPD management by treating the right patients with the right therapy at the right time during the course of their disease. Herein, we present a view on the current COPD management landscape and current unmet needs, and look to the future of COPD treatment and how patient care can be optimised. ER -